Page 16 - Section Editor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theragnostics Strengthens Board of Directors with Key Appointments Drug Development Experts Dr Dennis Langer and Professor Ken Herrmann Appointed as Non-Executive Directors LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board. Dr Dennis Langer has served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies, and has an extensive pharmaceutic...

Latest from our journals Authors | Editors | Researchers Share Post What would you say to your younger, Early Career Researcher self? Advice from Hindawi Editors on how to go about writing your first manuscript. We asked Hindawi Editors to share their advice and top tips when writing up a paper for the first time. Here’s what they said:  When you are done, your paper should say what you mean and not what you know how to say “I am a native English speaker, and I have been writing for a long time. It is still hard work. It takes almost as much time to write a good paper as it does to do...

PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders Leading experts in the field will advise on clinical development of PureTech’s lead, wholly-owned product candidate, LYT-100, in idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lu...

PureTech Health plc: PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the formation of its Clinical Advisory Board for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung d...

WHAT ROLES ARE AVAILABLE? Cherwell is run by a team of two editors-in-chief, five or six deputy editors and a team of section and deputy section editors overseeing each section. We also have a creative team who contribute to the art and images on our pieces. Deputy editor – deadline: 8pm Thursday, 4th March Deputy editors have worked on staff before and oversee several sections, managing lay-ins, proofing articles, and acting as a go-to for any questions section editors may have. As part of the senior editorial team, they can shape the editorial vision and are involved in broader decision-...